Results 231 to 240 of about 296,068 (343)

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Hepatic Histotripsy: Jet Ventilation Decreases the Effect of Respiratory Motion in A Porcine Liver Model. [PDF]

Cardiovasc Intervent Radiol
Winterholler JE, Kisting MA, Falk KL, Kisting AL, Jentink MS, White JK, Lubner MG, Laeseke PF, Knavel Koepsel EM, Swietlik JF, Hinshaw JL, Ferreira TH, Mao L, McCormick T, Cui M, Lee FT, Ziemlewicz TJ.   +16 more
europepmc   +1 more source

The Shareholder Wealth Maximization Norm and Industrial Organization

, 2001
Mark J. Roe
openalex   +2 more sources

The Case for Increasing Shareholder Power [PDF]

, 2003
Lucian A. Bebchuk
openalex   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

A dataset of venture capitalist types in China (1978-2021): A machine-human hybrid approach. [PDF]

Sci Data
Chen J, Cao R, Song Y, Hu A, Ding Y.
europepmc   +1 more source

Vom Lohnarbeiter zum Shareholder?

, 2001
Jan Priewe
openalex   +2 more sources

The New Look of Shareholder Litigation: Acquisition-Oriented Class Actions [PDF]

, 2003
Robert B. Thompson, Randall S. Thomas
openalex   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

Tissue Engineered Vascular Grafts: A Quarter Century Journey of Courage, Challenge, and Persistence. [PDF]

JACC Basic Transl Sci
Emmert MY, Generali M, Zilla P, Hoerstrup SP.   +3 more
europepmc   +1 more source